Mineralys Therapeutics, INC 8-K filings

Alexander Asam, Ph.D., a member of the Board of Directors at Mineralys Therapeutics, Inc., will not seek re-election at the company's 2024 annual meeting.

Mineralys Therapeutics has entered into an agreement for a potential $100 million at-the-market equity offering and reported its financial results for the fourth quarter and full year 2023, alongside a corporate update.

Mineralys Therapeutics has announced a $120 million private placement to fund the development of its lead drug candidate, lorundrostat, and for general corporate purposes.